Controlling Antibiotic Adverse Drug Reactions in Cystic Fibrosis
The majority of patients with cystic fibrosis experience at least 1 antibiotic adverse drug reaction.
Cystic Fibrosis
Elexacaftor-Tezacaftor-Ivacaftor Efficacious for Cystic Fibrosis
Percentage of FEV1 higher at four weeks and through 24 weeks with treatment versus placebo
MPR Weekly Dose Podcast: Episode 10
This week we talk about the resurrection of Biogen’s novel Alzheimer treatment; A “landmark” approval in cystic fibrosis; Expanded indication for Farxiga; The first topical minocycline formulation for acne vulgaris; and the Johnson & Johnson baby powder recall.
FDA Approves Triple Combination Therapy for Cystic Fibrosis
The Food and Drug Administration (FDA) has approved Trikafta (elexacaftor/tezacaftor/ivacaftor; Vertex) for the treatment of patients aged 12 years and older with cystic fibrosis (CF) who have ≥1 F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Trikafta is a fixed-dose combination containing elexacaftor 100mg, tezacaftor 50mg, and ivacaftor 75mg that is co-packaged…
Aspergillosis, ABPA-Related Hospitalizations in Cystic Fibrosis Confer Worse Outcomes
Nearly one-third of patients with cystic fibrosis-related hospitalizations have aspergillosis, which is associated with worse outcomes.
Lumacaftor-Ivacaftor Aids Cystic Fibrosis in Real-World Setting
Improved lung function, increased BMI, reduced need for IV antibiotics seen after one year of therapy
FDA to Review Elexacaftor, Tezacaftor, Ivacaftor Combo for Cystic Fibrosis
The Food and Drug Administration (FDA) has accepted for priority review the New Drug Application (NDA) for elexacaftor (VX-445), tezacaftor and ivacaftor triple combination regimen for patients with cystic fibrosis. Elexacaftor is an investigational therapy, while the combination of tezacaftor and ivacaftor and ivacaftor alone are both already approved treatments for cystic fibrosis. The NDA…
Novel Triple Combination Therapy for Cystic Fibrosis Submitted for FDA Review
A New Drug Application (NDA) for the investigational therapy elexacaftor (VX-445), for use in combination with tezacaftor and ivacaftor in the treatment of cystic fibrosis, has been submitted to the FDA by Vertex Pharmaceuticals. Elexacaftor and tezacaftor facilitate the cellular processing and trafficking of normal and select mutant forms of cystic fibrosis transmembrane conductance regulator…
Key Cystic Fibrosis Pathogens Reduced With Ivacaftor Use
Ivacaftor use linked to reductions in P. aeruginosa rates, prevalence of S. aureus, Aspergillus species
Inhaled Gallium Citrate Gets Orphan Drug Designation for Lung Infection Tx in Cystic Fibrosis
AR-501, an inhaled formulation of gallium citrate, is a small molecule anti-infective with broad spectrum activity against Gram-negative and Gram-positive bacteria in vitro, including antibiotic-resistant strains.
